EP1934183A1 - Methods of preparing anhydrous aripiprazole form ii - Google Patents

Methods of preparing anhydrous aripiprazole form ii

Info

Publication number
EP1934183A1
EP1934183A1 EP06825291A EP06825291A EP1934183A1 EP 1934183 A1 EP1934183 A1 EP 1934183A1 EP 06825291 A EP06825291 A EP 06825291A EP 06825291 A EP06825291 A EP 06825291A EP 1934183 A1 EP1934183 A1 EP 1934183A1
Authority
EP
European Patent Office
Prior art keywords
aripiprazole
slurry
acetone
temperature
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06825291A
Other languages
German (de)
French (fr)
Inventor
Hagit Eisen-Nevo
Zhanna Pavlov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of EP1934183A1 publication Critical patent/EP1934183A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention encompasses methods of preparing anhydrous aripiprazole Form II.
  • Schizophrenia is the most common type of psychosis caused by excessive neurotransmission activity of the dopaminergic nervous system in the central nervous system.
  • a number of drugs which block the neurotransmission of dopaminergic receptor in the central nervous system have been developed for use in treating schizophrenia.
  • drugs developed are phenothiazine-type compounds such as chlorpromazine, butyrophenone-type compounds such as haloperidol, and benzamide-type compounds such as sulpiride. These drugs improve so-called positive symptoms in the acute period of schizophrenia such as hallucinations, delusions, and excitations.
  • Aripiprazole is a pyschotropic drug that exhibits high affinity for dopamine D 2 and D 3 , serotonin 5-HT 1A and 5-HT 2A receptors; moderate affinity for dopamine D 4 , serotonin 5-HT 2 c and 5-HT 7 , ⁇ -adrenergic and histamine H 1 receptors; and moderate affinity for the serotonin reuptake site.
  • Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors.
  • the mechanism of action of aripiprazole, as with other drugs having efficacy in schizophrenia, is unknown. It has been proposed, however, that the efficacy of aripiprazole is mediated through a combination of partial agonist activity at D 2 and 5-HT 1 A receptors and antagonist activity at 5-HT 2A receptors.
  • Type-I aripiprazole crystals can be prepared by recrystallizing aripiprazole from an ethanol solution or by heating aripiprazole hydrate at 80°C.
  • Type-II aripiprazole crystals can be prepared by heating the Type-I crystals at 130°C to 140°C for 15 hours. This process is not easily applied to an industrial scale preparation of anhydride aripiprazole.
  • PCT publication WO 03/26659 discloses the preparation of anhydrous aripiprazole Type I and crystalline Forms A, B, C, D, E, F. and G.
  • the powder x-ray diffraction spectrum for aripiprazole Form C has characteristic peaks at 12.6°, 13.7°, 15.4°, 18.1°, 19.0°, 20.6°, 23.5°, and 26.4° 2-theta.
  • the process for preparing the crystalline forms comprises heating crystalline anhydrous aripiprazole.
  • the process is cumbersome because it requires crystalline anhydrous aripiprazole as the starting material.
  • the process can include drying or heating the aripiprazole which may affect the distribution of crystalline forms and/or crystalline purity, if drying causes crystalline transformation from one crystalline form to another.
  • the methods of the invention provide procedures that consistently and reproducibly yield Form II consistently to increase the arsenal of crystalline forms available to the skilled artisan in preparing pharmaceutical formulations.
  • One embodiment of the invention encompasses a method of preparing anhydrous aripiprazole Form II comprising slurrying aripiprazole in a solvent selected from the group consisting of: C 3 -C 8 ketones, THF, acetonitrile, butyl-acetate, dimethyl formamide (DMF), a mixture of tetrahydrofuran (THF) and IPA, water, diethyl ether (DEE) and acetone; heating the slurry; and isolating anhydrous aripiprazole Form II from the slurry.
  • the method can further comprise seeding the slurry with aripiprazole Form II prior to the heating step.
  • Another embodiment of the invention encompasses a method of preparing anhydrous aripiprazole Form II comprising providing a mixture of aripiprazole in acetone; heating the mixture at a temperature of about 56 0 C; cooling the mixture to room temperature; maintaining the mixture at a temperature of about 4 0 C for about 15 hours to obtain anhydrous aripiprazole Form II; providing a slurry of starting aripiprazole in acetone; seeding the slurry with the anhydrous aripiprazole Form II obtained from the mixture; heating the slurry at a temperature of about 25°C to about 5O 0 C; and isolating aripiprazole Form II.
  • Another embodiment of the invention encompasses a method of preparing anhydrous aripiprazole Form II comprising: providing a mixture of aripiprazole in a solvent selected from the group consisting of: C 3 -C 8 ketones, THF, acetonitrile, butyl- acetate, dimethyl formamide (DMF), a mixture of tetrahydrofuran (THF) and IPA, water, diethyl ether (DEE) and acetone; heating the mixture at a temperature of about 45 0 C to about the reflux temperature; cooling the mixture to a temperature of about 1O 0 C to about -2O 0 C; maintaining the mixture for about 15 minutes to about 60 hours to obtain anhydrous aripiprazole Form II; isolating the anhydrous aripiprazole Form II; providing a slurry of aripiprazole in a solvent selected from the group consisting of: C 3 -C 8 ketones, THF, acetonit
  • Another embodiment of the invention encompasses a method of preparing aripiprazole Form II comprising: combining aripiprazole and acetone to obtain a slurry; and seeding the slurry with aripiprazole Form II.
  • Figure 1 illustrates the powder X-ray diffraction pattern for Form II.
  • the process of the invention describes slurrying aripiprazole from a low boiling solvent such as acetone.
  • a low boiling solvent such as acetone.
  • the process is reproducible and consistent such that it can be applied in the large scale manufacture of crystalline aripiprazole.
  • the slurry in acetone reduces the amounts of solvent used during crystallization, thus yielding a significant economical and ecological advantage.
  • Aripiprazole Form II prepared by the method of the invention, is disclosed in WO 05/058835, hereby incorporated by reference. As disclosed therein, aripiprazole Form II is characterized by X-ray powder diffraction peaks at 16.5, 18.7, 21.9, 22.4 and 23.5 degrees two-theta ⁇ 0.2 degrees two-theta.
  • the aripiprazole crystalline Form II used for seeding can be made in situ or obtained as described in the PCT publication WO 05/058835.
  • Aripiprazole Form XII and Compound 2 are also disclosed in WO 05/058835.
  • aripiprazole Form XII is characterized by X-ray powder diffraction peaks at 17.4, 18.2, 19.7 and 24.5 degrees two-theta ⁇ 0.2 degrees two-theta; and aripiprazole compound 2 is characterized by X-ray powder diffraction peaks at 8.8, 14.5, 17.8, 20.5 and 22.2 degrees two-theta ⁇ 0.2 degrees two-theta.
  • the invention encompasses a method of preparing anhydrous aripiprazole Form II comprising slurrying a starting aripiprazole in a solvent selected from the group consisting of: C 3 -C 8 ketones, THF, acetonitrile, butyl-acetate, dimethyl formamide (DMF), a mixture of tetrahydrofuran (THF) and IPA, water, diethyl ether (DEE) and acetone; heating the slurry; and isolating anhydrous aripiprazole Form II from the slurry.
  • the method can further comprise seeding the slurry with aripiprazole Form II prior to the heating step.
  • the amount of aripiprazole Form II used for seeding is about 0.05% to 5% by weight of the aripiprazole.
  • the starting aripiprazole is selected from the group consisting of: crystalline aripiprazole Form XII, Compound 2, Form C, anhydrate, hydrate, solvate and mixtures thereof.
  • the solvent is acetone.
  • the amount of the solvent should be sufficient to form a slurry with the aripiprazole.
  • the ratio of starting aripiprazole to acetone is about 3:1 to about 20:1 ml of acetone per gram of aripiprazole. More preferably, the ratio of starting aripiprazole to acetone is about 3:1 to about 6:1 ml of acetone to gram of aripiprazole.
  • 30 g of aripiprazole 90 to 180 mL of acetone can be used.
  • the slurry is heated to a temperature of about 25°C to about 5O 0 C. More preferably, the slurry is heated to a temperature of about 3O 0 C to about 5O 0 C.
  • the slurry is maintained at the temperature for at least 1 hour, preferably from about 2 hours to about 22 hours.
  • the anhydrous aripiprazole Form II can be isolated by any method known in the art.
  • the anhydrous aripiprazole Form II can be separated by filtering the slurry or decanting the solvent from the slurry.
  • the isolating method can further comprise washing and drying the anhydrous aripiprazole Form II.
  • the anhydrous aripiprazole Form II is dried at a temperature of about 3O 0 C to about 6O 0 C, more preferably, at a temperature of about 4O 0 C to about 53 0 C under reduced pressure.
  • Another embodiment of the invention encompasses a method of preparing anhydrous aripiprazole Form II comprising: providing a mixture of aripiprazole in a solvent selected from the group consisting of: C 3 -C 8 ketones, THF, acetonitrile, butyl- acetate, dimethyl formamide (DMF), a mixture of tetrahydrofuran (THF) and IPA, water, diethyl ether (DEE) and acetone; heating the mixture at a temperature of about 45 0 C to about the reflux temperature; cooling the mixture to a temperature of about 1O 0 C to about -20 0 C; maintaining the mixture for about 15 minutes to about 60 hours to obtain anhydrous aripiprazole Form II; isolating the anhydrous aripiprazole Form II; providing a slurry of aripiprazole in a solvent selected from the group consisting of: C 3 -C 8 ketones, THF, acetonitrile
  • the aripiprazole used in the process is selected from the group consisting of: crystalline aripiprazole Form XII, Compound 2, Form C, anhydrate, hydrate, solvate and mixtures thereof.
  • the solvent is acetone.
  • the mixture is heated to a temperature of about 56 0 C.
  • the cooling is to a temperature of about 4°C.
  • the cooled mixture is maintained for about 15 hours.
  • the amount of aripiprazole Form II used for seeding is about 0.05% to 5% by weight of the starting aripiprazole.
  • the ratio of acetone to aripiprazole in the slurry is about 3:1 to about 20:1 ml of acetone per gram of aripiprazole. More preferably, the ratio of acetone to aripiprazole in the slurry is about 3:1 to about 6:1 ml of acetone per gram of aripiprazole.
  • the slurry can be prepared using the conditions and reagents described above.
  • Aripiprazole Form II can be isolated using the methods described above.
  • Another embodiment of the invention encompasses a method of preparing aripiprazole Form II comprising: combining aripiprazole and acetone to obtain a slurry; and seeding the slurry with aripiprazole Form II.
  • the starting aripiprazole in crystalline form (30 g), acetone (90-180 ml) and aripiprazole Form II (0.015 to 1.5 g) were introduced into a 250 ml reactor.
  • the mixture was heated at 25 0 C to 5O 0 C and stirred for at least 1 hr. Then, the mixture was cooled to room temperature and stirred for at least 10 min.
  • the precipitate, wet aripiprazole Form II was collected by filtration and washed with 30 ml of acetone.
  • the wet aripiprazole Form II was dried under vacuum at 40 0 C to 53 0 C overnight. Dry aripiprazole Form II was obtained.
  • Table 1 The results are summarized in Table 1.
  • Example 14 Preparation of Aripiprazole Form II by slurry in acetone including seeding of Aripiprazole Form II
  • Aripiprazole Form XII (10.8 Kg wet or 10 Kg dry), acetone (40 L) and aripiprazole Form II (200 g) were introduced into 100 L reactor. The mixture was heated to 48 0 C and stirred for 2 hr. Then, the mixture was cooled to room temperature and stirred for 1 hour. Aripiprazole Form II was collected by filtration and washed with 10 L of acetone. The wet aripiprazole Form II was dried under vacuum at 49 0 C for 4 hours. 9.5 Kg of dry aripiprazole Form II was obtained.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Provided is a method of preparing aripiprazole anhydrous Form II from aripiprazole.

Description

METHODS OF PREPARING ANHYDROUS ARIPIPRAZOLE FORM II
RELATED APPLICATIONS This application claims the benefit of U.S. provisional Application Serial Nos.
60/722,616, filed on September 29, 2005; 60/726,456, filed on October 12, 2005; and 60/737,092, filed on November 15, 2005, hereby incorporated by reference.
FIELD OF THE INVENTION The invention encompasses methods of preparing anhydrous aripiprazole Form II.
BACKGROUND OF THE INVENTION Schizophrenia is the most common type of psychosis caused by excessive neurotransmission activity of the dopaminergic nervous system in the central nervous system. A number of drugs which block the neurotransmission of dopaminergic receptor in the central nervous system have been developed for use in treating schizophrenia. Among the drugs developed are phenothiazine-type compounds such as chlorpromazine, butyrophenone-type compounds such as haloperidol, and benzamide-type compounds such as sulpiride. These drugs improve so-called positive symptoms in the acute period of schizophrenia such as hallucinations, delusions, and excitations. Many drugs for treating schizophrenia, however, are not effective for improving the so-called negative symptoms which are observed in the chronic period of schizophrenia such as apathy, emotional depression, and hypopsychosis. The drugs currently used produce undesirable side effects such as akathisia, dystonia, Parkinsonism dyskinesia, and late dyskinesia, by blocking the neurotransmission of dopaminergic receptor in the striate body. Drugs that improve both the negative and positive symptoms of schizophrenia but diminish the undesirable side effect of schizophrenia are particularly desirable.
Aripiprazole is a pyschotropic drug that exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors; moderate affinity for dopamine D4, serotonin 5-HT2c and 5-HT7, ^-adrenergic and histamine H1 receptors; and moderate affinity for the serotonin reuptake site. Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors. The mechanism of action of aripiprazole, as with other drugs having efficacy in schizophrenia, is unknown. It has been proposed, however, that the efficacy of aripiprazole is mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors.
U.S. patent No. 5,006,528 and Japanese Patent Kokai No. 02-191256 disclose that anhydride crystals of aripiprazole are typically manufactured by recrystallization of anhydride aripiprazole from ethanol or by heating aripiprazole hydrate at a temperature of 80°C.
The Proceedings of the 4th Japanese-Korean Symposium on Separation Technology (October 6-8, 1996) disclosed that aripiprazole anhydride crystals may exist as Type-I and Type-II crystals. According to this reference, Type-I aripiprazole crystals can be prepared by recrystallizing aripiprazole from an ethanol solution or by heating aripiprazole hydrate at 80°C. Type-II aripiprazole crystals can be prepared by heating the Type-I crystals at 130°C to 140°C for 15 hours. This process is not easily applied to an industrial scale preparation of anhydride aripiprazole.
PCT publication WO 03/26659 discloses the preparation of anhydrous aripiprazole Type I and crystalline Forms A, B, C, D, E, F. and G. The powder x-ray diffraction spectrum for aripiprazole Form C has characteristic peaks at 12.6°, 13.7°, 15.4°, 18.1°, 19.0°, 20.6°, 23.5°, and 26.4° 2-theta. Typically, the process for preparing the crystalline forms comprises heating crystalline anhydrous aripiprazole. The process, however, is cumbersome because it requires crystalline anhydrous aripiprazole as the starting material. The process can include drying or heating the aripiprazole which may affect the distribution of crystalline forms and/or crystalline purity, if drying causes crystalline transformation from one crystalline form to another.
The methods of the invention provide procedures that consistently and reproducibly yield Form II consistently to increase the arsenal of crystalline forms available to the skilled artisan in preparing pharmaceutical formulations.
SUMMARY OF THE INVENTION One embodiment of the invention encompasses a method of preparing anhydrous aripiprazole Form II comprising slurrying aripiprazole in a solvent selected from the group consisting of: C3-C8 ketones, THF, acetonitrile, butyl-acetate, dimethyl formamide (DMF), a mixture of tetrahydrofuran (THF) and IPA, water, diethyl ether (DEE) and acetone; heating the slurry; and isolating anhydrous aripiprazole Form II from the slurry. Optionally, the method can further comprise seeding the slurry with aripiprazole Form II prior to the heating step. Another embodiment of the invention encompasses a method of preparing anhydrous aripiprazole Form II comprising providing a mixture of aripiprazole in acetone; heating the mixture at a temperature of about 560C; cooling the mixture to room temperature; maintaining the mixture at a temperature of about 40C for about 15 hours to obtain anhydrous aripiprazole Form II; providing a slurry of starting aripiprazole in acetone; seeding the slurry with the anhydrous aripiprazole Form II obtained from the mixture; heating the slurry at a temperature of about 25°C to about 5O0C; and isolating aripiprazole Form II.
Another embodiment of the invention encompasses a method of preparing anhydrous aripiprazole Form II comprising: providing a mixture of aripiprazole in a solvent selected from the group consisting of: C3-C8 ketones, THF, acetonitrile, butyl- acetate, dimethyl formamide (DMF), a mixture of tetrahydrofuran (THF) and IPA, water, diethyl ether (DEE) and acetone; heating the mixture at a temperature of about 450C to about the reflux temperature; cooling the mixture to a temperature of about 1O0C to about -2O0C; maintaining the mixture for about 15 minutes to about 60 hours to obtain anhydrous aripiprazole Form II; isolating the anhydrous aripiprazole Form II; providing a slurry of aripiprazole in a solvent selected from the group consisting of: C3-C8 ketones, THF, acetonitrile, butyl-acetate, dimethyl formamide (DMF), a mixture of tetrahydrofuran (THF) and EPA, water, diethyl ether (DEE) and; seeding the slurry with the anhydrous aripiprazole Form II obtained from the mixture; heating the slurry at a temperature of about 25°C to about 500C; and isolating aripiprazole Form II.
Another embodiment of the invention encompasses a method of preparing aripiprazole Form II comprising: combining aripiprazole and acetone to obtain a slurry; and seeding the slurry with aripiprazole Form II.
BRIEF DESCRIPTION OF THE FIGURES Figure 1 illustrates the powder X-ray diffraction pattern for Form II.
DETAILED DESCRIPTION OF THE INVENTION The process of the invention describes slurrying aripiprazole from a low boiling solvent such as acetone. The process is reproducible and consistent such that it can be applied in the large scale manufacture of crystalline aripiprazole. During the process the slurry in acetone reduces the amounts of solvent used during crystallization, thus yielding a significant economical and ecological advantage.
Aripiprazole Form II, prepared by the method of the invention, is disclosed in WO 05/058835, hereby incorporated by reference. As disclosed therein, aripiprazole Form II is characterized by X-ray powder diffraction peaks at 16.5, 18.7, 21.9, 22.4 and 23.5 degrees two-theta ± 0.2 degrees two-theta. The aripiprazole crystalline Form II used for seeding can be made in situ or obtained as described in the PCT publication WO 05/058835. Aripiprazole Form XII and Compound 2 are also disclosed in WO 05/058835. As disclosed therein, aripiprazole Form XII is characterized by X-ray powder diffraction peaks at 17.4, 18.2, 19.7 and 24.5 degrees two-theta ± 0.2 degrees two-theta; and aripiprazole compound 2 is characterized by X-ray powder diffraction peaks at 8.8, 14.5, 17.8, 20.5 and 22.2 degrees two-theta ± 0.2 degrees two-theta.
The invention encompasses a method of preparing anhydrous aripiprazole Form II comprising slurrying a starting aripiprazole in a solvent selected from the group consisting of: C3-C8 ketones, THF, acetonitrile, butyl-acetate, dimethyl formamide (DMF), a mixture of tetrahydrofuran (THF) and IPA, water, diethyl ether (DEE) and acetone; heating the slurry; and isolating anhydrous aripiprazole Form II from the slurry. Optionally, the method can further comprise seeding the slurry with aripiprazole Form II prior to the heating step. Typically, the amount of aripiprazole Form II used for seeding is about 0.05% to 5% by weight of the aripiprazole.
Preferably, the starting aripiprazole is selected from the group consisting of: crystalline aripiprazole Form XII, Compound 2, Form C, anhydrate, hydrate, solvate and mixtures thereof.
Preferably, the solvent is acetone.
The amount of the solvent should be sufficient to form a slurry with the aripiprazole. Preferably, the ratio of starting aripiprazole to acetone is about 3:1 to about 20:1 ml of acetone per gram of aripiprazole. More preferably, the ratio of starting aripiprazole to acetone is about 3:1 to about 6:1 ml of acetone to gram of aripiprazole. Thus for example, when 30 g of aripiprazole is used 90 to 180 mL of acetone can be used.
Preferably, the slurry is heated to a temperature of about 25°C to about 5O0C. More preferably, the slurry is heated to a temperature of about 3O0C to about 5O0C. Preferably, prior to the isolation step the slurry is maintained at the temperature for at least 1 hour, preferably from about 2 hours to about 22 hours. The anhydrous aripiprazole Form II can be isolated by any method known in the art. For example, the anhydrous aripiprazole Form II can be separated by filtering the slurry or decanting the solvent from the slurry. The isolating method can further comprise washing and drying the anhydrous aripiprazole Form II. Preferably, the anhydrous aripiprazole Form II is dried at a temperature of about 3O0C to about 6O0C, more preferably, at a temperature of about 4O0C to about 530C under reduced pressure.
Another embodiment of the invention encompasses a method of preparing anhydrous aripiprazole Form II comprising: providing a mixture of aripiprazole in a solvent selected from the group consisting of: C3-C8 ketones, THF, acetonitrile, butyl- acetate, dimethyl formamide (DMF), a mixture of tetrahydrofuran (THF) and IPA, water, diethyl ether (DEE) and acetone; heating the mixture at a temperature of about 450C to about the reflux temperature; cooling the mixture to a temperature of about 1O0C to about -200C; maintaining the mixture for about 15 minutes to about 60 hours to obtain anhydrous aripiprazole Form II; isolating the anhydrous aripiprazole Form II; providing a slurry of aripiprazole in a solvent selected from the group consisting of: C3-C8 ketones, THF, acetonitrile, butyl-acetate, dimethyl formamide (DMF)5 a mixture of tetrahydrofuran (THF) and IPA, water, diethyl ether (DEE) and; seeding the slurry with the anhydrous aripiprazole Form II obtained from the mixture; heating the slurry at a temperature of about 250C to about 5O0C; and isolating aripiprazole Form II.
Preferably, the aripiprazole used in the process is selected from the group consisting of: crystalline aripiprazole Form XII, Compound 2, Form C, anhydrate, hydrate, solvate and mixtures thereof.
Preferably, the solvent is acetone.
Preferably, the mixture is heated to a temperature of about 560C.
Preferably, the cooling is to a temperature of about 4°C.
Preferably, the cooled mixture is maintained for about 15 hours.
Preferably, the amount of aripiprazole Form II used for seeding is about 0.05% to 5% by weight of the starting aripiprazole.
Preferably, the ratio of acetone to aripiprazole in the slurry is about 3:1 to about 20:1 ml of acetone per gram of aripiprazole. More preferably, the ratio of acetone to aripiprazole in the slurry is about 3:1 to about 6:1 ml of acetone per gram of aripiprazole.
The slurry can be prepared using the conditions and reagents described above.
Aripiprazole Form II can be isolated using the methods described above. Another embodiment of the invention encompasses a method of preparing aripiprazole Form II comprising: combining aripiprazole and acetone to obtain a slurry; and seeding the slurry with aripiprazole Form II.
Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The invention is further defined by reference to the following examples describing in detail the analysis of the aripiprazole crystalline forms and methods for preparing the crystalline forms of the invention. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.
EXAMPLES Examples 1-13: Preparation of Aripiprazole Form II by slurry in acetone including seeding of Aripiprazole Form II
The starting aripiprazole in crystalline form (30 g), acetone (90-180 ml) and aripiprazole Form II (0.015 to 1.5 g) were introduced into a 250 ml reactor. The mixture was heated at 250C to 5O0C and stirred for at least 1 hr. Then, the mixture was cooled to room temperature and stirred for at least 10 min. The precipitate, wet aripiprazole Form II, was collected by filtration and washed with 30 ml of acetone. The wet aripiprazole Form II was dried under vacuum at 400C to 530C overnight. Dry aripiprazole Form II was obtained. The results are summarized in Table 1.
Example 14: Preparation of Aripiprazole Form II by slurry in acetone including seeding of Aripiprazole Form II
Aripiprazole Form XII (10.8 Kg wet or 10 Kg dry), acetone (40 L) and aripiprazole Form II (200 g) were introduced into 100 L reactor. The mixture was heated to 480C and stirred for 2 hr. Then, the mixture was cooled to room temperature and stirred for 1 hour. Aripiprazole Form II was collected by filtration and washed with 10 L of acetone. The wet aripiprazole Form II was dried under vacuum at 490C for 4 hours. 9.5 Kg of dry aripiprazole Form II was obtained.

Claims

CLAIMS What is claimed is:
1. A method of preparing anhydrous aripiprazole Form II comprising: slurrying a starting aripiprazole in a solvent selected from the group consisting of: C3-C8 ketones, THF, acetonitrile, butyl-acetate, dimethyl formamide (DMF), a mixture of tetrahydrofuran (THF) and IPA, water, diethyl ether (DEE) and acetone; heating the slurry; and isolating anhydrous aripiprazole Form II from the slurry.
2. The method according to claim 1 further comprising seeding the slurry with aripiprazole Form II prior to heating.
3. The method according to claim 2, wherein the amount of aripiprazole Form II used for seeding is about 0.05% to 5% by weight of the starting aripiprazole.
4. The method according to any of the preceding claims, wherein the starting aripiprazole is selected from the group consisting of: crystalline aripiprazole Form XII, Compound 2, Form C, anhydrate, hydrate, solvate and mixtures thereof.
5. The method according to any of the preceding claims, wherein the solvent is acetone.
6. The method according to claim 5, wherein the ratio of acetone to aripiprazole is 3 : 1 to about 20:1 ml of acetone to gram of starting aripiprazole.
7. The method according to claim 5, wherein the ratio of acetone to aripiprazole is about 3:1 to about 6:1 ml of acetone to gram of starting aripiprazole.
8. The method according to any of the preceding claims, wherein the heating to a temperature of about 250C to about 5O0C.
9. The method according to any of the preceding claims, wherein the heating is carried out at a temperature of about 3O0C to about 5O0C.
10. The method according to any of the preceding claims, further comprising maintaining the slurry prior to the isolation step.
11. The method according to claim 10, wherein the slurry is maintained for at least 1 hour.
12. The method according to any of claims 10 and 11, wherein the slurry is maintained for about 2 hours to about 22 hours.
13. The method according to any of the preceding claims, wherein the isolation is by filtering the slurry.
14. The method according to any of the preceding claims, wherein the isolation is by decanting the solvent from the slurry.
15. The method according to any of claims 13 and 14, further comprising washing and drying the anhydrous aripiprazole Form II.
16. The method according to claim 15, wherein the anhydrous aripiprazole Form II is dried at a temperature of about 3O0C to about 6O0C under reduced pressure.
17. The method according to any of claims 15 and 16, wherein the anhydrous aripiprazole Form II is dried at a temperature of about 4O0C to about 530C under reduced pressure.
18. A method of preparing anhydrous aripiprazole Form II comprising: providing a mixture of aripiprazole in a solvent selected from the group consisting of: C3-C8 ketones, THF, acetonitrile, butyl-acetate, dimethyl formamide (DMF), a mixture of tetrahydrofuran (THF) and IPA, water, diethyl ether (DEE) and acetone; heating the mixture at a temperature of about 450C to about the reflux temperature; cooling the mixture to a temperature of about 100C to about -2O0C; maintaining for about 15 minutes to about 60 hours to obtain anhydrous aripiprazole Form II; isolating the anhydrous aripiprazole Form II; providing a slurry of starting aripiprazole in a solvent selected from the group consisting of: C3-C8 ketones, THF, acetonitrile, butyl-acetate, dimethyl formamide
(DMF), a mixture of tetrahydrofuran (THF) and IPA, water, diethyl ether (DEE); seeding the slurry with the anhydrous aripiprazole Form II obtained from the mixture; heating the slurry at a temperature of about 250C to about 500C; and isolating aripiprazole Form EL
19. The method according to claim 18, wherein the aripiprazole is at least one of aripiprazole Form XII, Compound 2, or Form C or anhydrate, hydrate, solvate and mixtures thereof.
20. The method according to any of claims 18 and 19, wherein the solvent is acetone.
21. The method according to any of claims 18, 19, and 20, wherein the heating of the mixture is to a temperature of about 560C.
22. The method according to any of claims 18, 19, 20, and 21, wherein the cooling is to a temperature of about 4°C.
23. The method according to any of claims 18, 19, 20, 21, and 22, wherein the cooled mixture is maintained for about 15 hours.
24. The method according to any of claims 18, 19, 20, 21, 22, and 23, wherein the amount of aripiprazole Form II used for seeding is about 0.05% to 5% by weight of the starting aripiprazole.
25. The method according to any of claims 18, 19, 20, 21, 22, 23, and 24, wherein the ratio of acetone to aripiprazole in the slurry is about 3:1 to about 20:1 ml of acetone per gram of starting aripiprazole.
26. The method according to any of claims 18, 19, 20, 21, 22, 23, and 24, wherein the ratio of acetone to aripiprazole in the slurry is about 3:1 to about 6:1 ml of acetone per gram of starting aripiprazole.
27. The method according to any of claims 18, 19, 20, 21, 22, 23, 24, 25, and 26, wherein the slurry is heated to a temperature of about 3O0C to about 5O0C.
28. The method according to claim 18, further comprising maintaining the slurry prior to the isolation step.
29. The method according to claim 28, wherein the slurry is maintained for at least 1 hour.
30. The method according to any of claims 28 and 29, wherein the slurry is maintained for about 2 hours to about 22 hours.
31. The method according to any of claims 18-30, wherein the isolation is by filtering the slurry.
32. The method according to any of claims 18-31, wherein the isolation is by decanting the solvent from the slurry.
33. The method according to any of claims 31 and 32, further comprising washing and drying the anhydrous aripiprazole Form II.
34. The method according to claim 33, wherein the anhydrous aripiprazole Form II is dried at a temperature of about 3O0C to about 6O0C under reduced pressure.
35. A method of preparing aripiprazole Form II comprising: combining aripiprazole and acetone to obtain a slurry; and seeding the slurry with aripiprazole Form II.
EP06825291A 2005-09-29 2006-09-29 Methods of preparing anhydrous aripiprazole form ii Withdrawn EP1934183A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72261605P 2005-09-29 2005-09-29
US72645605P 2005-10-12 2005-10-12
US73709205P 2005-11-15 2005-11-15
PCT/US2006/038279 WO2007041414A1 (en) 2005-09-29 2006-09-29 Methods of preparing anhydrous aripiprazole form ii

Publications (1)

Publication Number Publication Date
EP1934183A1 true EP1934183A1 (en) 2008-06-25

Family

ID=37670930

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06825291A Withdrawn EP1934183A1 (en) 2005-09-29 2006-09-29 Methods of preparing anhydrous aripiprazole form ii

Country Status (7)

Country Link
EP (1) EP1934183A1 (en)
JP (1) JP2008521835A (en)
KR (1) KR20070088750A (en)
BR (1) BRPI0606163A2 (en)
IL (1) IL186278A0 (en)
MX (1) MX2007006368A (en)
WO (1) WO2007041414A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101340214B1 (en) * 2011-03-31 2013-12-10 주식회사 대웅제약 Process for the preparation of anhydrous Aripiprazole crystal form II
CN102850268B (en) * 2011-06-27 2015-07-15 上海中西制药有限公司 Aripiprazole I-type crystallite, aripiprazole solid preparation and preparation methods thereof
KR101372840B1 (en) * 2012-08-02 2014-03-12 주식회사 에스텍파마 Method for preparing anhydrous aripiprazole crystals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (en) 1988-10-31 1997-05-14 大塚製薬 株式会社 Schizophrenia remedy
AR033485A1 (en) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd MEDICINAL SUBSTANCE OF ARIPIPRAZOL OF LOW HYGROSCOPICITY AND PROCESS FOR THE PREPARATION OF THE SAME
WO2005058835A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007041414A1 *

Also Published As

Publication number Publication date
BRPI0606163A2 (en) 2009-05-26
IL186278A0 (en) 2008-01-20
WO2007041414A1 (en) 2007-04-12
MX2007006368A (en) 2007-07-11
KR20070088750A (en) 2007-08-29
JP2008521835A (en) 2008-06-26

Similar Documents

Publication Publication Date Title
JP4700813B2 (en) Telmisartan polymorph, process for its preparation and its use for the preparation of pharmaceutical compositions
EP2951158B1 (en) Process for the preparation of ivacaftor and solvates thereof
CN107155326A (en) (2S,3S)‑7‑fluoro‑2‑(4‑fluorophenyl)‑3‑(1‑methyl‑1H‑1,2,4‑triazole‑5‑yl)‑4‑oxo‑1 , Coformer salt of 2,3,4-tetrahydroquinoline-5-carboxylic acid methyl ester and preparation method thereof
CA2550726A1 (en) Methods of preparing aripiprazole crystalline forms
EP3337485B1 (en) Crystalline forms of ibrutinib
AU2011256287A1 (en) A crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
CN101111481A (en) Process for preparing crystalline aripiprazole
WO2016131431A1 (en) Solid forms of empagliflozin
EP2093217B1 (en) Process for preparing Form X of aripiprazole
CA2595334C (en) Polymorphic forms of aripiprazole and processes for making
EP3027626A1 (en) A process for preparing rifaximin k
US20050277650A1 (en) Process for preparing aripirazole hydrate
EP1765782A1 (en) Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril
WO2007041414A1 (en) Methods of preparing anhydrous aripiprazole form ii
WO2004085426A1 (en) Novel crystalline forms of candesartan cilexetil
WO2011153221A1 (en) Solid state forms of ixabepilone
US7714129B2 (en) Methods of preparing anhydrous aripiprazole form II
AU2012204839A1 (en) Method for resolution of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan- 1-yl)-3,3-dimethyl-piperazine
WO2008130534A1 (en) Crystalline forms of topotecan hydrochloride and processes for making the same
JP7236458B2 (en) Synthesis of triazoloquinazolinones
CN101277935A (en) Process for the preparation of anhydrous aripiprazole form II
EP2448936A2 (en) Processes for the preparation of form i and form ii of palonosetron hydrochloride
KR101340214B1 (en) Process for the preparation of anhydrous Aripiprazole crystal form II
WO2008135966A1 (en) Process for the purification of optically impure 2-(2-(3(s)-(3-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxy-propyl)phenyl-2-propanol
WO2014009969A2 (en) Novel polymorphs of azilsartan

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070522

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080716

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120301